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anes for ovarian and breast cancer, proton pump inhibi-
tors in the treatment of dyspepsia, glycoprotein IIb/IIIa
inhibitors, methylphenidate for hyperactivity in child-
hood, zanamivir, and rosiglitazone for type II Diabetes
Mellitus. The analysis of the evidence shows that the ef-
fectiveness of these drugs has been demonstrated in the
last 12 years. However, cost-effectiveness evidence has
been published for 70% of the drugs with an average de-
lay of 3 years (range 0–10). The cost-effectiveness of
those, introduced after 1995 (80% of all included drugs/
drug groups), has been demonstrated using models only,
if at all. CONCLUSIONS: Cost-effectiveness evidence is
produced with a lag behind the effectiveness evidence. As
a result, decision-makers are in a position of awaiting
sound evidence while issuing guidance based on current
inconclusive research results. The cost to society is dis-
cussed, and establishing the cost-effectiveness of new
drugs alongside RCTs at an earlier stage of their develop-
ment is suggested.
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BACKGROUND: As more European governments re-
quire economic data to support reimbursement applica-
tions the potential burden of multiple economic evalua-
tions is being seen as a problem by industry. Placing
responsibility for cost-effectiveness assessment at the Eu-
ropean level using standardised methods has been pro-
posed as a solution. OBJECTIVE: To review the feasibil-
ity of a European level cost-effectiveness test for new
drugs, from conceptual, practical and political view-
points. METHODS: The issues are examined first from
the theoretical perspective—does a European level eco-
nomic evaluation have any inherent logic. Secondly, the
practical issues of how such an evaluation might be con-
ducted are examined. Could it be based on a phase III
clinical trial? The political issues relate to who would reg-
ulate the production of such cost-effectiveness data; who
would use the data to assist in what decision(s)? Different
regulatory models are assessed using the analogy of drug
licensing. DISCUSSION: The position generally taken by
economists is that a generalised cost-effectiveness result is
neither possible nor useful. Differences in the price struc-
tures, treatment patterns and provider incentives between
systems make generalisations of cost-effectiveness of
questionable relevance. How fast will European integra-
tion produce a single health market? Moves towards a
single European price for each drug are relevant as in the
willingness of European states to allow the EU to play a
bigger role in health care financing and organisation.
Will countries accept each others’ assessments or will an
EU agency like EMEA be required? CONCLUSIONS:
Long-term political and economic changes may well cre-
ate a true European market in which cost-effectiveness at
the European level will have meaning and relevance.
Meanwhile, individual country health care systems seem
more concerned with short-term budget impact when
making new drugs available. The pharmaceutical indus-
try should not anticipate a reduction in the overall de-
mand for locally targeted economic information.
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PATIENT ADHERENCE TO DRUG THERAPY IN A 
THREE-TIER COPAYMENT STRUCTURE
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BACKGROUND: The three-tier copayment plan is de-
signed to reduce the cost of pharmacy benefits to the in-
surer or payer while maintaining patient choice. Because
the patient pays a larger portion of the cost of middle-
and high-tier drugs, some have argued that this plan de-
sign may adversely impact patient drug utilization for
chronic medications. OBJECTIVE: To determine whether
a three-tier copayment structure adversely affects patient
drug utilization for middle- and upper-tier drugs for dia-
betes and depression. METHODS: We conducted a lon-
gitudinal, retrospective claims database study using claims
data from a national pharmaceutical benefits management
company. Claims for two chronic conditions, depression
and oral diabetes, were examined for patients on three-tier
copayment plans and for patients on an open formulary
plan with the same copayment for every drug. Average
rates of patient adherence, number of prescriptions filled,
and days of therapy were calculated. RESULTS: There
were statistically significant differences in rates of patient
adherence, number of prescriptions filled, days of therapy,
amount of copay, and payer costs among patients using
drugs in the lower, middle, or upper tier of the three-tier
structure. In addition, average patient adherence, number
of prescriptions filled, and days of therapy did differ signif-
icantly for patients on an open formulary compared to pa-
tients on a three-tier copayment structure. These differ-
ences were largely a function of sample size, and may be of
little practical utility.CONCLUSIONS: The larger patient
copayment for medications in the middle and upper tiers
of a three-tier copayment structure have only a minimal
impact on drug utilization in the antidepressant and oral
diabetes drug categories. Further research is needed to de-
termine whether these findings would be replicated when
applied to other therapeutic classes.
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All patients are entitled to equal access to health care re-
sources. The Department of Pharmacoeconomics at Uni-
versity of Texas MD Anderson Cancer Center (UTM-
DACC) administers a Patient Assistance Program (PAP)
that provides assistance to indigent patients with free
pharmaceuticals for their therapy. Drug cost is recovered
through a drug reimbursement program offered by phar-
maceutical companies. OBJECTIVE: The objective of
this report is to examine trends in drug cost savings to in-
digent patients at UTMDACC using the PAP model.
METHODS: A retrospective study using data from Sep-
tember 1996 to August 2000 was conducted to determine
the value of the program. Patients were enrolled in this
program if they qualified based on the Financial Classifi-
cation Scale. Uninsured patients as well as under-insured
patients were considered in this study. Data was analyzed
to evaluate the trend in cost savings for the three fiscal
years. RESULTS: Over $334 million was spent on drug
cost over the period. There was an average increase of
22% per year in drug cost. The indigent patients ac-
counted for 9% of the total patient population at UTM-
DACC. An estimated $33 million was spent on drugs for
indigent patients during that period. The PAP system re-
covered a total of $16.8 million; $4.1M (1997), $4.3M
(1998), $3.5M (1999), and $4.9M (2000). This accounts
for 51% in drug cost recovery through this program. The
fluctuation in cost saving was attributed to changes in the
number of programs, number of patients enrolled, and
product mix. CONCLUSION: The PAP system has pro-
vided free drugs to patients without financial resources
and reduced the economic burden of this population on
the health care institution. The program has created
goodwill between the pharmaceutical companies, the
health care institution, the patients and the community.
NO SPECIFIC OR MULTIPLE DISEASES-QUALITY 
OF LIFE & PREFERENCE-BASED MEASURES
PQP1
LESSONS LEARNED FROM DEVELOPING A 
PSYCHOMETRICALLY BASED SEDATION 
QUESTIONNAIRE IN PHARMACOLOGICALLY 
PARALYZED CRITICALLY ILL PATIENTS
Kane SL, Dasta JF, Pathak DS
The Ohio State University, Columbus, OH, USA
OBJECTIVE: To share lessons learned from developing a
reliable and valid questionnaire for adequacy of sedation
in pharmacologically paralyzed critically ill patients.
METHODS: In phase 1, seven experts listed 21 charac-
teristics describing anxiety in pharmacologically para-
lyzed patients. In phase 2, two scenarios were created il-
lustrating the experience of paralysis: one with and one
without receiving a sedative. A convenience sample of 30
people evaluated scenarios to determine the importance
of characteristics obtained from phase 1 using a five-
point scale. Items were reduced to the 10 most important
characteristics (mean 
3). Based on these results, the fi-
nal instrument consisted of 12 questions: 2 categorical
addressing memory of the experience and 10 referred to
characteristics of anxiety. In phase 3, two groups of criti-
cally ill patients were administered the questionnaire: 1)
sedated only and 2) sedated and pharmacologically para-
lyzed. The questionnaire was administered twice for reli-
ability. Questionnaire results were compared to subjec-
tive and objective sedation monitoring tools for validity.
Calculated sample size was 20 for each group. RESULTS:
During six months, 21 patients consented to participate.
Twelve patients died and nine patients (6 sedated, 3 se-
dated/paralyzed) were administered questionnaires. Five
patients (3 sedated, 2 sedated/paralyzed) did not remem-
ber the intensive care unit experience. Two of three pa-
tients in the sedated group who answered the question-
naire found it difficult to remember over time. One
sedated/paralyzed patient who answered the question-
naire received a sedative without amnesic properties and
felt anxious during therapy. The distressful feeling of this
patient was comparable to findings of the objective seda-
tion tool. CONCLUSIONS: Mortality in this critically ill
patient population was high. Due to amnestic properties
of sedatives most patients did not remember the experi-
ence. Of patients who remembered, their memory deteri-
orated over time. Based on lessons learned, it may require
2–3 years to achieve the necessary sample size.
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INTRODUCTION: The ERIQA Group aims to create
guidance for European regulatory authorities on the as-
sessment of the quality of HRQL studies in clinical trials
and to evaluate the validity of HRQL claims. OBJEC-
TIVES: To identify disease or drugs in which a formal
HRQL assessment is recommended. To identify measures
and methods recommended. To evaluate the reliability of
recommendations across documents. METHODS: Infor-
mations were searched on the EMEA website (www.
eudra.org/emea.html). A research was performed with
the two key words: “Quality of life” and “QoL”. All the
documents retrieved were reviewed. RESULTS: 133 doc-
uments were retrieved excluding duplicates (129: Quality
of Life, 25: QoL). 19 documents derived from the Effi-
cacy Working Parties (EWP) including nine notes for
guidance (Weight Control, Cancer, Chronic Peripheral
Arterial Occlusive Disease, Cardiac Failure, Stable An-
gina Pectoris, Antiarrythmics, Parkinson, Alzheimer,
Multiple Sclerosis), concept paper (3), points to consider
(5) and position statements (2). Only one document was
a note for guidance for ICH. 104 European Public As-
sessment Report (EPAR) were retrieved, representing 26
products. Nine miscellaneous documents were found in-
